Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17632961 | 0.84 | DGKA (0.36) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL3461124 | 0.79 | SMN1; SMN2 (0.41) | TSHRSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL10608782 | 0.79 | TSHR (0.36) | TSHRHSD17B10ALDH1A1 | |
| SCHEMBL13273386 | 0.79 | TSHR (0.33) | TSHRHSD17B10 | |
| SCHEMBL12786282 | 0.78 | MVD (0.38) | — | |
| SCHEMBL12769059 | 0.75 | CA1 (0.43) | MAPTBLMHSD17B10 | |
| SCHEMBL22110077 | 0.75 | TSHR (0.43) | TSHRHSD17B10LMNATDP1 | |
| SCHEMBL7035531 | 0.75 | CYP1A2 (0.38) | DGKAMAPTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL17640897 | 0.74 | TP53 (0.33) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL18068957 | 0.74 | TSHR (0.36) | TSHRSMN1; SMN2HSD17B10ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287245-B2 | Liquid thioether carboxylic acid esters | BASF SE (DE) | 2019-05-14 | — | — | US | disclosed |
| US-20180127363-A1 | LIQUID THIOETHER CARBOXYLIC ACID ESTERS | BASF SE (DE) | 2018-05-10 | — | — | US | disclosed |
| US-20180127363-A1 | LIQUID THIOETHER CARBOXYLIC ACID ESTERS | BASF SE (DE) | 2018-05-10 | — | — | US | disclosed |
| WO-2016046292-A1 | LIQUID THIOETHER CARBOXYLIC ACID ESTERS | BASF SE (DE) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127363-A1 | LIQUID THIOETHER CARBOXYLIC ACID ESTERS | ALAD, TIPRL, CA7 | DGKA 2746/4885TLR2 817/4885ADRA2A 4557/4885 |
| US-10287245-B2 | Liquid thioether carboxylic acid esters | ALAD, TIPRL, CA7 | DGKA 2746/4885TLR2 817/4885ADRA2A 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.